Krystal Biotech (KRYS) EBT Margin (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of EBT Margin data on file, last reported at 52.79% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 335.0% year-over-year to 52.79%; the trailing twelve-month figure through Mar 2026 stood at 49.67% (up 828.0% YoY), and the FY2025 full-year result was 48.69%, up 1587.0% from the prior year.
• EBT Margin rose to 52.79% in Q1 2026, from 47.74% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 943.75% in Q3 2023 to a low of 2.06% in Q1 2024.
• A 4-year average of 120.95% and a median of 48.7% in 2025 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin tumbled 90824 bps in 2024 and jumped 4738 bps in 2025, its largest moves.
• Tracing KRYS's EBT Margin over 4 years: stood at 25.29% in 2023, then soared by 111 bps to 53.34% in 2024, then dropped by 10 bps to 47.74% in 2025, then climbed by 11 bps to 52.79% in 2026.
• Business Quant data shows KRYS's EBT Margin at 52.79% in Q1 2026, 47.74% in Q4 2025, and 49.05% in Q3 2025.